Anti-Human IGF1R (CD221) (Teprotumumab) - 50 mg

2 - 8°C Wet Ice

The insulin-like growth factor-1 receptor (IGF1R) is a key receptor tyrosine kinase thatregulates cell growth, proliferation, and survival, playing a critical role in cancer developmentand progression. Overexpression of IGF1R is commonly observed in various cancers, whereit promotes tumor growth, transformation, motility, and metastasis. Targeting IGF1R hasbecome a promising therapeutic approach, with strategies including the reduction of receptorexpression, inhibition of kinase activity through small-molecule inhibitors, disruption ofreceptor function using monoclonal antibodies, and neutralization of its ligands. A deeperunderstanding of the downstream signaling pathways and IGF1R's role in different cancertypes is essential for developing more effective treatments1, 2. Teprotumumab has shown significant potential, particularly in the treatment of thyroid eyedisease (TED). Its effectiveness stems from its ability to inhibit IGF1R, which is linked to thethyrotropin receptor, a central factor in TED's pathology. However, teprotumumab therapy isassociated with side effects such as hyperglycemia, hearing changes, fatigue, musclespasms, hair loss, weight loss, gastrointestinal issues, menstrual irregularities, and infusionreactions. Recognizing and managing these adverse effects is crucial for optimizingteprotumumab’s use in clinical practice, ensuring a favorable balance between its risks andbenefits3, 4.

≥ 5.0 mg/ml

IGF1R (Insulin-like Growth Factor 1 Receptor) is primarily found on thesurface of human cells and is a transmembrane receptor activated by insulin-like growthfactor 1 (IGF-1) and IGF-21. It is widely expressed in various tissues, including the brain, liver, muscle, and bone.